MX2017011087A - Derivados de tetrahidropiranil benzamida. - Google Patents
Derivados de tetrahidropiranil benzamida.Info
- Publication number
- MX2017011087A MX2017011087A MX2017011087A MX2017011087A MX2017011087A MX 2017011087 A MX2017011087 A MX 2017011087A MX 2017011087 A MX2017011087 A MX 2017011087A MX 2017011087 A MX2017011087 A MX 2017011087A MX 2017011087 A MX2017011087 A MX 2017011087A
- Authority
- MX
- Mexico
- Prior art keywords
- tetrahydropyranyl
- benzamide derivatives
- compounds
- benzamide
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención proporciona compuestos de la fórmula (1), en donde R, R1-R3 son como se describen en la presente; métodos para tratar pacientes por diabetes usando los compuestos y procesos para preparar los compuestos. (ver Fórmula).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2015/073563 WO2016138631A1 (en) | 2015-03-03 | 2015-03-03 | Imidazo benzamide compounds |
PCT/CN2016/074083 WO2016138821A1 (en) | 2015-03-03 | 2016-02-19 | Tetrahydropyranyl benzamide derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017011087A true MX2017011087A (es) | 2017-11-10 |
Family
ID=56849060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017011087A MX2017011087A (es) | 2015-03-03 | 2016-02-19 | Derivados de tetrahidropiranil benzamida. |
Country Status (24)
Country | Link |
---|---|
US (1) | US10196385B2 (es) |
EP (1) | EP3265460A4 (es) |
JP (1) | JP2018507232A (es) |
KR (1) | KR20170106483A (es) |
CN (1) | CN107406436B (es) |
AU (1) | AU2016228055B2 (es) |
BR (1) | BR112017015448A2 (es) |
CA (1) | CA2975413A1 (es) |
CL (1) | CL2017002148A1 (es) |
CO (1) | CO2017008721A2 (es) |
CR (1) | CR20170354A (es) |
DO (1) | DOP2017000196A (es) |
EA (1) | EA201791745A1 (es) |
EC (1) | ECSP17058071A (es) |
IL (1) | IL253405A0 (es) |
MA (1) | MA41641A (es) |
MX (1) | MX2017011087A (es) |
PE (1) | PE20171650A1 (es) |
PH (1) | PH12017501560A1 (es) |
SG (1) | SG11201706718RA (es) |
SV (1) | SV2017005520A (es) |
TN (1) | TN2017000372A1 (es) |
WO (2) | WO2016138631A1 (es) |
ZA (1) | ZA201704948B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018014337A1 (en) * | 2016-07-22 | 2018-01-25 | Eli Lilly And Company | 3-Chloro-N- [ (1R, 3S) -3- [5- (3, 5-dimethylimidazol-4-yl) -4H-1, 2, 4-triazol-3-yl] cyclohexyl] -N-methyl-benzamide |
CN117720541A (zh) | 2018-03-09 | 2024-03-19 | 里科瑞尔姆Ip控股有限责任公司 | 取代的1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2430821T3 (es) | 2006-10-10 | 2013-11-21 | Amgen Inc. | Compuestos de N-arilpirazol para usar contra la diabetes |
US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
EP2404896A1 (en) * | 2009-03-05 | 2012-01-11 | Shionogi&Co., Ltd. | Cyclohexane derivative having npy y5 receptor antagonism |
JP2013517272A (ja) * | 2010-01-15 | 2013-05-16 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗糖尿病化合物としてのオキサジアゾール・ベータ・カルボリン誘導体 |
WO2012123449A1 (en) | 2011-03-14 | 2012-09-20 | Boehringer Ingelheim International Gmbh | N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators |
WO2015120610A1 (en) | 2014-02-14 | 2015-08-20 | Eli Lilly And Company | Gpr142 agonist compound |
-
2015
- 2015-03-03 WO PCT/CN2015/073563 patent/WO2016138631A1/en active Application Filing
-
2016
- 2016-02-18 MA MA041641A patent/MA41641A/fr unknown
- 2016-02-19 CA CA2975413A patent/CA2975413A1/en not_active Abandoned
- 2016-02-19 CR CR20170354A patent/CR20170354A/es unknown
- 2016-02-19 KR KR1020177024303A patent/KR20170106483A/ko not_active Application Discontinuation
- 2016-02-19 WO PCT/CN2016/074083 patent/WO2016138821A1/en active Application Filing
- 2016-02-19 SG SG11201706718RA patent/SG11201706718RA/en unknown
- 2016-02-19 JP JP2017546161A patent/JP2018507232A/ja active Pending
- 2016-02-19 EP EP16758437.4A patent/EP3265460A4/en not_active Withdrawn
- 2016-02-19 EA EA201791745A patent/EA201791745A1/ru unknown
- 2016-02-19 BR BR112017015448A patent/BR112017015448A2/pt not_active IP Right Cessation
- 2016-02-19 TN TNP/2017/000372A patent/TN2017000372A1/en unknown
- 2016-02-19 CN CN201680013049.8A patent/CN107406436B/zh active Active
- 2016-02-19 US US15/118,295 patent/US10196385B2/en active Active
- 2016-02-19 MX MX2017011087A patent/MX2017011087A/es unknown
- 2016-02-19 AU AU2016228055A patent/AU2016228055B2/en not_active Expired - Fee Related
- 2016-02-19 PE PE2017001456A patent/PE20171650A1/es not_active Application Discontinuation
-
2017
- 2017-07-10 IL IL253405A patent/IL253405A0/en unknown
- 2017-07-20 ZA ZA2017/04948A patent/ZA201704948B/en unknown
- 2017-08-21 DO DO2017000196A patent/DOP2017000196A/es unknown
- 2017-08-22 SV SV2017005520A patent/SV2017005520A/es unknown
- 2017-08-23 CL CL2017002148A patent/CL2017002148A1/es unknown
- 2017-08-28 CO CONC2017/0008721A patent/CO2017008721A2/es unknown
- 2017-08-30 PH PH12017501560A patent/PH12017501560A1/en unknown
- 2017-09-01 EC ECIEPI201758071A patent/ECSP17058071A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2016228055A1 (en) | 2017-08-17 |
SG11201706718RA (en) | 2017-09-28 |
US20180194755A1 (en) | 2018-07-12 |
CN107406436A (zh) | 2017-11-28 |
ECSP17058071A (es) | 2017-10-31 |
ZA201704948B (en) | 2019-02-27 |
IL253405A0 (en) | 2017-09-28 |
WO2016138631A1 (en) | 2016-09-09 |
DOP2017000196A (es) | 2017-09-15 |
TN2017000372A1 (en) | 2019-01-16 |
MA41641A (fr) | 2018-01-09 |
JP2018507232A (ja) | 2018-03-15 |
SV2017005520A (es) | 2018-08-27 |
US10196385B2 (en) | 2019-02-05 |
WO2016138821A1 (en) | 2016-09-09 |
AU2016228055B2 (en) | 2018-06-07 |
CL2017002148A1 (es) | 2018-04-13 |
EA201791745A1 (ru) | 2018-01-31 |
PE20171650A1 (es) | 2017-11-13 |
BR112017015448A2 (pt) | 2018-01-30 |
EP3265460A4 (en) | 2018-08-08 |
CA2975413A1 (en) | 2016-09-09 |
CR20170354A (es) | 2017-09-05 |
KR20170106483A (ko) | 2017-09-20 |
EP3265460A1 (en) | 2018-01-10 |
PH12017501560A1 (en) | 2018-02-05 |
CO2017008721A2 (es) | 2018-01-05 |
CN107406436B (zh) | 2021-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501192B1 (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
MY196413A (en) | Substituted Carbonucleoside Derivatives Useful as Anticancer Agents | |
GEP20207160B (en) | New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
PH12017500416A1 (en) | Compounds and compositions as raf kinase inhibitors | |
TW201613886A (en) | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones | |
PH12019501690A1 (en) | Pyrimidine compound and pharmaceutical use thereof | |
MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
PH12017500653A1 (en) | Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes | |
NZ761519A (en) | Nlrp3 modulators | |
NZ730250A (en) | 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators | |
PH12019502093A1 (en) | Novel ester compounds, method for the production thereof and use thereof | |
TW201613878A (en) | Pyrazine GPR40 agonists for the treatment of type II diabetes | |
PH12014501712B1 (en) | Novel morpholinyl derivatives useful as mogat-2-inhibitors | |
MX2018011877A (es) | Proceso mejorado para la preparacion de tartrato de butorfanol. | |
MX2022006229A (es) | Composiciones y metodos para el tratamiento de resistencia a la insulina. | |
PH12016501613B1 (en) | Pyrazines modulators of gpr6 | |
TN2016000177A1 (en) | P-substituted asymmetric ureas and medical uses thereof | |
PH12017501560A1 (en) | Tetrahydropyranyl benzamide derivatives | |
MX367852B (es) | Derivados de isotiazol como agonistas del gpr120 para el tratamiento de la diabetes tipo ii. | |
MX2019000542A (es) | Derivados de pirazolilaminobenzimidazol como inhibidores de jak. | |
GB2564185A (en) | Process for the preparation of derivatives of benzodioxole | |
PH12017501147A1 (en) | Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs | |
MX2017005669A (es) | Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos. | |
MX2016009250A (es) | Nuevos imidazoles para el tratamiento y profilaxis de la infeccion por virus sincicial respiratorio. |